🇺🇸 FDA
Patent

US 8865748

Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

granted A61KA61K31/4418A61P

Quick answer

US patent 8865748 (Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer) held by Akebia Therapeutics, Inc. expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Akebia Therapeutics, Inc.
Grant date
Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4418, A61P, A61P1/00, A61P1/02